VistaGen

VistaGen shakes up Phase III social anxiety disorder program
VistaGen shakes up Phase III social anxiety disorder program
Clinical Trials Arena
VistaGen
clinical trials
social anxiety
fasedienol
Flag link:
VistaGen finds open-label success with social anxiety nasal spray, but PALISADE pivotal trial remains iced
VistaGen finds open-label success with social anxiety nasal spray, but PALISADE pivotal trial remains iced
Fierce Biotech
VistaGen
nasal spray
social anxiety
open-label
PH94B
Flag link:
Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks
Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks
Fierce Biotech
VistaGen
FDA
clinical trials
anxiety
PH94B
Flag link:
Vistagen acquires Pherin Pharmaceuticals for 12.4M shares and 'nominal' cash
Vistagen acquires Pherin Pharmaceuticals for 12.4M shares and 'nominal' cash
Endpoints
VistaGen
Pherin Pharmaceuticals
M&A
Flag link:
Walls close in on VistaGen's PALISADE anxiety trial program in wake of phase 3 failure
Walls close in on VistaGen's PALISADE anxiety trial program in wake of phase 3 failure
Fierce Biotech
VistaGen
anxiety
clinical trials
social anxiety
Flag link:
VistaGen can’t puff out phase 3 success for social anxiety nasal spray
VistaGen can’t puff out phase 3 success for social anxiety nasal spray
Fierce Biotech
VistaGen
social anxiety
clinical trials
PH94B
Flag link:
VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
Fierce Biotech
VistaGen
social anxiety
PH94B
clinical trials
FDA
Flag link:
VistaGen fails phase 2 depression trial, sparking stock rout
VistaGen fails phase 2 depression trial, sparking stock rout
Fierce Biotech
VistaGen
AV-101
major depressive disorder
clinical trials
Flag link:
VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain Treatment Programs
VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain Treatment Programs
BioSpace
VistaGen
AV-101
FDA
fast track
neuropathic pain
BioWave
Virpax Pharmaceuticals
Flag link:
VistaGen raises $36M for stem cell tech
VistaGen raises $36M for stem cell tech
Fierce Biotech
stem cells
VistaGen
Flag link: